-
公开(公告)号:US20230192654A1
公开(公告)日:2023-06-22
申请号:US17969479
申请日:2022-10-19
申请人: PFIZER, INC.
发明人: Lei Zhang , Erik Alphie LaChapelle , Christopher Ryan Butler , Natasha Mariam Kablaoui , Michael Aaron Brodney , Laura Ann McAllister , Qingyi Yang , Christopher John Helal , Damien Webb
IPC分类号: C07D401/14 , C07D401/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/107
CPC分类号: C07D401/14 , C07D401/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/107
摘要: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
-
公开(公告)号:US20230019853A1
公开(公告)日:2023-01-19
申请号:US17341877
申请日:2021-06-08
申请人: Pfizer Inc.
发明人: Christopher Ryan Butler , Michelle Renee Garnsey , Kevin Alexander Ogilvie , Jana Polivkova , Matthew Forrest Sammons , Aaron Christopher Smith , Qingyi Yang
IPC分类号: C07D471/20 , C07D519/00
摘要: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
-
公开(公告)号:US11452711B2
公开(公告)日:2022-09-27
申请号:US17660270
申请日:2022-04-22
申请人: Pfizer Inc.
发明人: Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC分类号: C07D403/12 , A61K31/403 , A61P31/14 , A61K31/427 , A61K31/401
摘要: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US11351149B2
公开(公告)日:2022-06-07
申请号:US17395139
申请日:2021-08-05
申请人: Pfizer Inc.
发明人: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC分类号: C07D403/12 , A61K31/403 , A61P31/14 , A61K31/427
摘要: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US11203594B2
公开(公告)日:2021-12-21
申请号:US16849329
申请日:2020-04-15
申请人: Pfizer Inc.
发明人: Samit Kumar Bhattacharya , Douglas Carl Behenna , Kimberly O. Cameron , Ping Chen , John M. Curto , Kevin Daniel Freeman-Cook , Mehran Jalaie , Robert Steven Kania , Yajing Lian , Sajiv Krishnan Nair , Cynthia Louise Palmer , Martin Youngjin Pettersson , Eugene Yuanjin Rui , Matthew Sammons , Qingyi Yang , Liying Zhang
IPC分类号: C07D471/04 , A61P9/12
摘要: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.
-
公开(公告)号:US20230120254A1
公开(公告)日:2023-04-20
申请号:US17932151
申请日:2022-09-14
申请人: Pfizer Inc.
发明人: Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC分类号: A61K31/403 , A61P31/14 , A61K31/427 , C07D403/12 , A61K31/401
摘要: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US20220062232A1
公开(公告)日:2022-03-03
申请号:US17395139
申请日:2021-08-05
申请人: Pfizer Inc.
发明人: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Liuqing Wei , Qingyi Yang , Xiaojing Yang
IPC分类号: A61K31/403 , C07D403/12 , A61K31/427 , A61P31/14
摘要: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US20200331909A1
公开(公告)日:2020-10-22
申请号:US16849329
申请日:2020-04-15
申请人: Pfizer Inc.
发明人: Samit Kumar Bhattacharya , Douglas Carl Behenna , Kimberly O. Cameron , Ping Chen , John M. Curto , Kevin Daniel Freeman-Cook , Mehran Jalaie , Robert Steven Kania , Yajing Lian , Sajiv Krishnan Nair , Cynthia Louise Palmer , Martin Youngjin Pettersson , Eugene Yuanjin Rui , Matthew Sammons , Qingyi Yang , Liying Zhang
IPC分类号: C07D471/04 , A61P9/12
摘要: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.
-
公开(公告)号:US20230339930A1
公开(公告)日:2023-10-26
申请号:US18004996
申请日:2021-07-07
申请人: Pfizer Inc.
发明人: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Qingyi Yang
IPC分类号: C07D417/14 , A61P31/14
CPC分类号: C07D417/14 , A61P31/14
摘要: The invention relates to compounds of Formula I
wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.-
公开(公告)号:US20230174532A1
公开(公告)日:2023-06-08
申请号:US18162052
申请日:2023-01-31
申请人: Pfizer Inc.
发明人: Christopher Ryan BUTLER , Michelle Renee GARNSEY , Kevin Alexander OGILVIE , Jana POLIVKOVA , Matthew Forrest SAMMONS , Aaron Christopher SMITH , Qingyi Yang
IPC分类号: C07D471/20 , C07D519/00
CPC分类号: C07D471/20 , C07D519/00 , C07B2200/13
摘要: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:
or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.
-
-
-
-
-
-
-
-
-